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Zidovudine/Lamivudine (AZT/3TC) are commonly used in HAART regimen as the 
backbone NRTI for first-line therapy in developing countries. A generic combination tablet 
of AZT/3TC is currently used in all government hospitals in Malaysia. Studies comparing 
safety and efficacy of generic AZT/3TC are very limited. Thus, a retrospective 
observational cohort study was conducted to evaluate virological and immunological 
response, and anaemia incidence among patients treated with AZT/3TC. A total of 109 
samples were recruited, with 65 samples initiated innovator and 44 generic. Virological 
and immunological response in both cohort were similar. Although viral load suppression 
to undetectable level (< 50 copies/ml) in generic group was slightly earlier as compared to 
innovator (median: seven months vs. eight months), this was not statistically significant (p 
= 0.550). Similarly, mean difference in terms of increment of CD4 cell count post 12 
months therapy and median duration to achieve CD4 count >350 cells/µl were not 
statistically significant (p = 0.505 and p = 0.190). Incidence of Zidovudine-induced 
anaemia were found in 10.8% (n = 7) in innovator and 15.9% (n = 7) in generic cohort, 
with median time to develop anaemia was two and three months respectively (p = 0.169). 
In conclusion, our ﬁndings demonstrated similar clinical outcomes in patients treated with 
either innovator or generic formulation of AZT/3TC in terms of virological and 
immunological response. The risk of developing Zidovudine–induced anaemia was also 
similar in both groups. Therefore, it is justifiable to use generic AZT/3TC as the backbone 
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